TW202241892A - 用於治療弗里德希氏運動失調症(friedreich's ataxia)之方法及化合物 - Google Patents

用於治療弗里德希氏運動失調症(friedreich's ataxia)之方法及化合物 Download PDF

Info

Publication number
TW202241892A
TW202241892A TW111100817A TW111100817A TW202241892A TW 202241892 A TW202241892 A TW 202241892A TW 111100817 A TW111100817 A TW 111100817A TW 111100817 A TW111100817 A TW 111100817A TW 202241892 A TW202241892 A TW 202241892A
Authority
TW
Taiwan
Prior art keywords
optionally substituted
alkyl
pharmaceutically acceptable
acceptable salt
independently
Prior art date
Application number
TW111100817A
Other languages
English (en)
Chinese (zh)
Inventor
阿西姆 安薩里
阿比 巴特
肖恩 杰弗里斯
普拉蒂克 沙
承智 張
Original Assignee
美商規劃醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商規劃醫療公司 filed Critical 美商規劃醫療公司
Publication of TW202241892A publication Critical patent/TW202241892A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)
TW111100817A 2021-01-08 2022-01-07 用於治療弗里德希氏運動失調症(friedreich's ataxia)之方法及化合物 TW202241892A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163135427P 2021-01-08 2021-01-08
US63/135,427 2021-01-08

Publications (1)

Publication Number Publication Date
TW202241892A true TW202241892A (zh) 2022-11-01

Family

ID=82358799

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111100817A TW202241892A (zh) 2021-01-08 2022-01-07 用於治療弗里德希氏運動失調症(friedreich's ataxia)之方法及化合物

Country Status (11)

Country Link
US (1) US20240124491A1 (https=)
EP (1) EP4274583A4 (https=)
JP (1) JP2024502469A (https=)
CN (1) CN117241805A (https=)
AR (1) AR124589A1 (https=)
AU (1) AU2022206424A1 (https=)
CA (1) CA3204523A1 (https=)
IL (1) IL304322A (https=)
MX (1) MX2023008153A (https=)
TW (1) TW202241892A (https=)
WO (1) WO2022150555A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024502469A (ja) * 2021-01-08 2024-01-19 デザイン セラピューティクス,インク. フリードライヒ運動失調症を治療するための方法及び化合物
JP2025502064A (ja) * 2022-01-06 2025-01-24 デザイン セラピューティクス,インク. フリードライヒ運動失調症を治療するための化合物及び方法
CN119708005A (zh) * 2023-09-27 2025-03-28 北京沐华生物科技有限责任公司 一类brd4蛋白降解剂化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270727A1 (en) * 2005-05-03 2006-11-30 Christian Melander Small molecule therapeutics and uses therefor
RU2720237C2 (ru) * 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
GB201504314D0 (en) * 2015-03-13 2015-04-29 Univ Dundee Small molecules
US10517877B2 (en) * 2016-03-30 2019-12-31 Wisconsin Alumni Research Foundation Compounds and methods for modulating frataxin expression
PT3442972T (pt) * 2016-04-15 2020-05-29 Abbvie Inc Inibidores de bromodomínio
WO2019204781A1 (en) * 2018-04-20 2019-10-24 Design Therapeutics Inc. Methods and compounds for the treatment of genetic disease
EP4234550A3 (en) * 2018-05-22 2023-09-06 Design Therapeutics, Inc. Methods and compounds for the treatment of genetic disease
US20220047596A1 (en) * 2018-09-12 2022-02-17 Board Of Regents, The University Of Texas System Combination of parp inhibitor and brd4 inhibitor for the treatment of cancer
CN121045206A (zh) * 2020-02-03 2025-12-02 设计治疗公司 用于治疗遗传疾病的方法和化合物
WO2022126000A1 (en) * 2020-12-11 2022-06-16 Design Therapeutics, Inc. Methods and compounds for modulating myotonic dystrophy 1
JP2024502469A (ja) * 2021-01-08 2024-01-19 デザイン セラピューティクス,インク. フリードライヒ運動失調症を治療するための方法及び化合物

Also Published As

Publication number Publication date
CA3204523A1 (en) 2022-07-14
IL304322A (en) 2023-09-01
MX2023008153A (es) 2023-09-21
AU2022206424A1 (en) 2023-08-24
AU2022206424A9 (en) 2024-09-19
WO2022150555A3 (en) 2022-12-22
CN117241805A (zh) 2023-12-15
JP2024502469A (ja) 2024-01-19
WO2022150555A2 (en) 2022-07-14
US20240124491A1 (en) 2024-04-18
EP4274583A4 (en) 2025-01-22
EP4274583A2 (en) 2023-11-15
AR124589A1 (es) 2023-04-12

Similar Documents

Publication Publication Date Title
US20240050576A1 (en) Methods and compounds for the treatment of genetic disease
EP4234553A2 (en) Methods and compounds for the treatment of genetic disease
TW202241892A (zh) 用於治療弗里德希氏運動失調症(friedreich's ataxia)之方法及化合物
US20240166693A1 (en) Methods and compounds for modulating myotonic dystropy 1
TW202334148A (zh) 用於治療弗里德希氏共濟失調(friedreich's ataxia)之化合物及方法
US20250276997A1 (en) Methods and compounds for the treatment of genetic disease
EP4234550A2 (en) Methods and compounds for the treatment of genetic disease
WO2021142315A1 (en) Methods and compounds for the treatment of fragile x
EP4257128A2 (en) Methods and compounds for the treatment of genetic disease
HK40103182A (zh) 用於治疗弗里德希氏共济失调的方法和化合物
HK40116639A (zh) 用於治疗弗里德希共济失调的化合物和方法
HK40104905A (zh) 用於调节强直性肌营养不良1型的方法和化合物
HK40090030A (zh) 用於治疗遗传疾病的方法和化合物
CN118695861A (zh) 用于治疗弗里德希共济失调的化合物和方法